Rapid Solutions for Point-of-Care Diagnostics Provided Worldwide

(San Diego, CA, USA) for the development and distribution of rapid clinical diagnostic solutions. Many new tests are in the development pipeline.

The long-term global alliance between Quidel and bioMérieux was originally formed in 2008. The two companies planned to codevelop new rapid tests using Quidel's rapid test development capability and bioMérieux's expertise in immunochemistry and wide-ranging library of biologics, including antibodies and antigens.

BioMerieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination. Its products are used for diagnosing infectious diseases, for providing results for cancer screening and monitoring, and cardiovascular emergencies.

Quidel develops rapid diagnostic tests that allow for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care, and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit.

Related Links:

bioMerieux
Quidel